_________
false
כן-פייט ביופרמה בע"מ
2
381
CAN-FITE BIOPHARMA LTD
Corporation no:
512022153
14960
Israel Securities Authority
Tel Aviv Stock Exchange
C003
(
Public
)
Reported via MAGNA:
05/05/2025
www.isa.gov.il
www.tase.co.il
Reference:
2025-02-031288
Time of broadcast:
13:36
13:36
The corporation scheduled the publication of the report to
05/05/2025 15:00
Other Report or Announcement
Regulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
ea024086301-6k_canfiteEDGAR2_Bannerless_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
-1
Date of revision of form structure:
06/08/2024
Address:
Bareket
10
,
Petach-Tikva
47190
,
Tel:
03-9241114
,
03-9213501
Fax:
03-9249378
E-mail address:
motti@canfite.co.il
Company site:
www.canfite.com
Previous names of reporting entity:
Name of the Signatory:
FARBSTEIN MORDECHAI
Position of Signatory in the reporting corporation:
Chief Operating Officer & CFO
Name of Employer Company:
Address:
Maharal street
10
,
Tel Aviv
6248110
Telephone:
052-8998671
Facsimile:
E-mail:
Motti@canfite.co.il
1